Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NV 52

Drug Profile

NV 52

Alternative Names: NV-07β

Latest Information Update: 12 Dec 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer Kazia Therapeutics
  • Class Anti-inflammatories; Isoflavones
  • Mechanism of Action Arachidonic acid inhibitors; Nitric oxide inhibitors; Superoxide dismutase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammatory-bowel-disease in Australia (PO)
  • 23 Dec 2010 NV 52 is still in phase I development for Inflammatory bowel disorders in Australia
  • 10 Aug 2006 Novogen has initiated enrolment in a phase I trial for Inflammatory bowel disease in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top